StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
FONR reports on 2026-05-18 during the day. Things to look at before the print:
Educational pre-print checklist — descriptive only, not a directional call.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $18.86 | $18.84 | -0.08% | 0.0M |
| 05-12 | $18.84 | $18.86 | +0.11% | 0.0M |
| 05-13 | $18.87 | $18.86 | -0.05% | 0.0M |
| 05-14 | $18.87 | $18.86 | -0.05% | 0.0M |
| 05-15 | $18.86 | $18.86 | +0.00% | 0.0M |
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Each factor shows FONR's percentile within the scored universe — observational ranking, not a recommendation.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $78.06M | $51.59M | $26.04M | $104.35M |
Operating Income | $9.94M | $7.12M | $3.68M | $13.78M |
Net Income | $5.96M | $4.32M | $2.26M | $8.33M |
EPS (Diluted) | $0.87 | $0.63 | $0.33 | $1.21 |
Total Assets | $219.22M | $217.22M | $218.35M | $216.91M |
Total Liabilities | $54.77M | $54.36M | $56.96M | $56.80M |
Cash & Equivalents | $53.65M | $52.98M | $54.28M | $56.33M |
Free Cash Flow OCF − CapEx | $1.00M | $-404.00K | $-177.00K | $7.47M |
Shares Outstanding | 6.87M | 6.87M | 6.87M | Not available |
No sell-side coverage available for FONR.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.